Skip to main content

ALTERACIONES EN EL PROCESAMIENTO DEL ARN EN LA ENFERMEDAD DE HUNTINGTON

SAF2015-65371-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Huntington's disease-specific mis-splicing unveils key effector genes and altered splicing factors

  • Elorza, Ainara
  • Márquez, Yamile
  • Cabrera, Jorge
  • Sánchez-Trincado, José Luis
  • Santos-Galindo, María
  • Hernández, Ivó H.
  • Picó, Sara
  • Díaz-Hernández, Juan I.
  • García-Escudero, Ramón
  • Irimia Martínez, Manuel
  • Lucas, José J.
Correction of mis-splicing events is a growing therapeutic approach for neurological diseases such as spinal muscular atrophy or neuronal ceroid lipofuscinosis 7, which are caused by splicing-affecting mutations. Non-mutation harboring mis-spliced effector genes are also good candidate therapeutic targets in diseases with more complex etiologies such as cancer, autism, muscular dystrophies or neurodegenerative diseases. Next-generation RNA sequencing (RNA-seq) has boosted investigation of global mis-splicing in diseased tissue to identify such key pathogenic mis-spliced genes. Nevertheless, while analysis of tumour or dystrophic muscle biopsies can be informative on early stage pathogenic mis-splicing, for neurodegenerative diseases, these analyses are intrinsically hampered by neuronal loss and neuroinflammation in post-mortem brains. To infer splicing alterations relevant to Huntington's disease (HD) pathogenesis, here we performed intersect-RNA-seq analyses of human post-mortem striatal tissue and of an early symptomatic mouse model in which neuronal loss and gliosis are not yet present. Together with a human/mouse parallel motif scan analysis, this approach allowed us to identify the shared mis-splicing signature triggered by the HD-causing mutation in both species and to infer upstream deregulated splicing factors. Moreover, we identified a plethora of downstream neurodegeneration-linked mis-spliced effector genes that -together with the deregulated splicing factors- become new possible therapeutic targets. In summary, here we report pathogenic global mis-splicing in HD striatum captured by our new intersect-RNA-seq approach that can be readily applied to other neurodegenerative diseases for which bona fide animal models are available., grants PI2015-2/06-3 and PI2018/06-1 ; by grants : SAF2015-65371-R (MINECO/AEI/FEDER, UE) ; RTI2018-096322-B-I00 (MCIU/AEI/FEDER, UE) from Spanish Ministry of Economy and Competitiveness/Ministry of Science, Innovation and Universities (MINECO/MICINN) to JJL and BFU2017-89201-P (MINECO/AEI/FEDER, UE) to MI; PI18/00263 from the Instituto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness) co-funded by the European Regional Development Fund- to RG-E; institutional grant from Fundación Ramón Areces to CBMSO ; Fundación BBVA to JJL; and by the European Research Council under the European Union's Horizon 2020 research and innovation program ERC-StG-LS2-637591 to MI
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus

  • Engel, Tobías
  • Gómez-Sintes, Raquel
  • Alves, Mariana
  • Jiménez-Mateos, Eva María
  • Fernández-Nogales, Marta
  • Sanz-Rodríguez, Amaya
  • Morgan, James
  • Beamer, Edward
  • Rodríguez-Matellán, Alberto G.
  • Dunleavy, Mark
  • Takanori, Sano
  • Ávila, Jesús
  • Medina, Miguel
  • Hernández Pérez, Félix
  • Lucas, José Javier
  • Henshall, David C.
14 p.-5 fig., Glycogen synthase kinase-3 (GSK-3) is ubiquitously expressed throughout the brain and involved in vital molecular pathways such as cell survival and synaptic reorganization and has emerged as a potential drug target for brain diseases. A causal role for GSK-3, in particular the brain-enriched GSK-3β isoform, has been demonstrated in neurodegenerative diseases such as Alzheimer's and Huntington's, and in psychiatric diseases. Recent studies have also linked GSK-3 dysregulation to neuropathological outcomes in epilepsy. To date, however, there has been no genetic evidence for the involvement of GSK-3 in seizure-induced pathology. Status epilepticus (prolonged, damaging seizure) was induced via a microinjection of kainic acid into the amygdala of mice. Studies were conducted using two transgenic mouse lines: a neuron-specific GSK-3β overexpression and a neuron-specific dominant-negative GSK-3β (GSK-3β-DN) expression in order to determine the effects of increased or decreased GSK-3β activity, respectively, on seizures and attendant pathological changes in the hippocampus. GSK-3 inhibitors were also employed to support the genetic approach. Status epilepticus resulted in a spatiotemporal regulation of GSK-3 expression and activity in the hippocampus, with decreased GSK-3 activity evident in non-damaged hippocampal areas. Consistent with this, overexpression of GSK-3β exacerbated status epilepticus-induced neurodegeneration in mice. Surprisingly, decreasing GSK-3 activity, either via overexpression of GSK-3β-DN or through the use of specific GSK-3 inhibitors, also exacerbated hippocampal damage and increased seizure severity during status epilepticus. In conclusion, our results demonstrate that the brain has limited tolerance for modulation of GSK-3 activity in the setting of epileptic brain injury. These findings caution against targeting GSK-3 as a treatment strategy for epilepsy or other neurologic disorders where neuronal hyperexcitability is an underlying pathomechanism., This work was supported by funding from the Sixth Framework Programme (MIRG-CT-2004-014567, to D.C.H.) a IRCSET-Marie Curie International Mobility Fellowship, the Health Research Board (PD/2009/31 to T.E. and HRA_POR/ 2011/41 to D.C.H.); Science Foundation Ireland (13/SIRG/2098 and 17/CDA/ 4708 to T.E. and 16/RC/3948 to D.C.H.) and co-funded under the European Regional Development Fund and by FutureNeuro industry partners;); from the H2020 Marie Skłowdowksa-Curie Actions Individual Fellowship (753527 to E.B.); from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklowdowska-Cuire grant agreement (No. 766124 to T.E.); grants from Ministerio de Economía Industria y Competitividad of Spain SAF2009-08233 and SAF2015-65371-R to J.J.L., SAF2016-78603-R to M.M. and BFU2016-77885-P to F.H.; grant PI2015-2/06-3 from CIBERNED-ISCIII to J.J.L.; and institutional grants to CBMSO from Fundación Ramón Areces and Fundación Banco de Santander., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Autism-like phenotype and risk gene mRNA deadenylation by CPEB4 mis-splicing

  • Parras, Alberto
  • Anta, Héctor
  • Santos-Galindo, María
  • Swarup, Vivek
  • Elorza, Ainara
  • Nieto-González, J.
  • Picó, Sara
  • Hernández, Ivó H.
  • Díaz-Hernández, Juan I.
  • Belloc, Eulàlia
  • Rodolosse, Annie
  • Parikshak, Neelroop N.
  • Peñagarikano, Olga
  • Fernández-Chacón, Rafael
  • Irimia, Manuel
  • Navarro, Pilar
  • Geschwind, Daniel H.
  • Méndez, Raúl
  • Lucas, José Javier
Common genetic contributions to autism spectrum disorder (ASD) reside in risk gene variants that individually have minimal effect sizes. As environmental factors that perturb neurodevelopment also underlie idiopathic ASD, it is crucial to identify altered regulators that can orchestrate multiple ASD risk genes during neurodevelopment. Cytoplasmic polyadenylation element binding proteins 1–4 (CPEB1–4) regulate the translation of specific mRNAs by modulating their poly(A)-tails and thereby participate in embryonic development and synaptic plasticity. Here we find that CPEB4 binds transcripts of most high-confidence ASD risk genes. The brains of individuals with idiopathic ASD show imbalances in CPEB4 transcript isoforms that result from decreased inclusion of a neuron-specific microexon. In addition, 9% of the transcriptome shows reduced poly(A)-tail length. Notably, this percentage is much higher for high-confidence ASD risk genes, correlating with reduced expression of the protein products of ASD risk genes. An equivalent imbalance in CPEB4 transcript isoforms in mice mimics the changes in mRNA polyadenylation and protein expression of ASD risk genes and induces ASD-like neuroanatomical, electrophysiological and behavioural phenotypes. Together, these data identify CPEB4 as a regulator of ASD risk genes., This work was supported by grants: ISCIII-CiberNed-PI2013/09 & -PI2015-2/06 (J.J.L., R.F.-C.), FEDER-PI14/00125 & -PI17/00199 (P.N.), MINECO-SAF2012-34177 & -SAF2015-65371-R (J.J.L.), FEDER-BFU2014-54122-P (R.M.), -BFU2014-55076-P (M.I.), -BFU2016-76050-P (R.F.-C.), -SEV-2012-0208 to CRG by European Union FEDER (M.I.); NIMH 5R37 MH060233, 5R01 MH09714 and 5R01 MH100027 (D.H.G.); Junta de Andalucía-P12-CTS-2232 & -CTS-600 (R.F.-C.); Generalitat de Catalunya-2014/SGR/143 (P.N.); ERC-StG-LS2-637591 (M.I.); and from Fundación Botín-Banco Santander/Santander Universities Global Division, Fundación BBVA, and Fundación Ramón Areces. A.P. was recipient of a MICINN FPI-fellowship; N.N.P. was supported by the NRSA F30 MH099886, UCLA Medical Scientist Training Program and V.S. by a Larry Hillblom Postdoctoral Fellowship. We thank the computing facilities of Extremadura Research Centre for Advanced Technologies (CETA-CIEMAT/Government of Spain), which is funded by ERDF. Tissue, biological specimens or data used in this research were obtained from the Autism BrainNet (formerly the Autism Tissue Program), which is sponsored by the Simons Foundation, and the University of Maryland Brain and Tissue Bank (a component of the NIH NeuroBioBank).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Differential regulation of Kidins220 isoforms in Huntington's disease

  • Sebastián-Serrano, Álvaro
  • Simón-García, Ana
  • Belmonte-Alfaro, Alicia
  • Pose-Utrilla, Julia
  • Santos-Galindo, María
  • Puerto, Ana del
  • García-Guerra, Lucía
  • Hernández, Ivó H.
  • Schiavo, Giampietro
  • Campanero, Miguel R.
  • Lucas, José Javier
  • Iglesias, Teresa
Huntington's disease (HD) is an inherited progressive neurodegenerative disease characterized by brain atrophy particularly in the striatum that produces motor impairment, and cognitive and psychiatric disturbances. Multiple pathogenic mechanisms have been proposed including dysfunctions in neurotrophic support and calpain-overactivation, among others. Kinase D-interacting substrate of 220 kDa (Kidins220), also known as ankyrin repeat-rich membrane spanning (ARMS), is an essential mediator of neurotrophin signaling. In adult brain, Kidins220 presents two main isoforms that differ in their carboxy-terminal length and critical protein-protein interaction domains. These variants are generated through alternative terminal exon splicing of the conventional exon 32 (Kidins220-C32) and the recently identified exon 33 (Kidins220-C33). The lack of domains encoded by exon 32 involved in key neuronal functions, including those controlling neurotrophin pathways, pointed to Kidins220-C33 as a form detrimental for neurons. However, the functional role of Kidins220-C33 in neurodegeneration or other pathologies, including HD, has not been explored. In the present work, we discover an unexpected selective downregulation of Kidins220-C33, in the striatum of HD patients, as well as in the R6/1 HD mouse model starting at early symptomatic stages. These changes are C33-specific as Kidins220-C32 variant remains unchanged. We also find the early decrease in Kidins220-C33 levels takes place in neurons, suggesting an unanticipated neuroprotective role for this isoform. Finally, using ex vivo assays and primary neurons, we demonstrate that Kidins220-C33 is downregulated by mechanisms that depend on the activation of the protease calpain. Altogether, these results strongly suggest that calpain-mediated Kidins220-C33 proteolysis modulates onset and/or progression of HD., This work was supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (MCIU) grants to T.I. (SAF2017‐88885‐R), J.J.L. (SAF2015‐65371‐R) and M.R.C. (SAF2017‐88881‐R); by B2017/BMD‐3700 NEUROMETAB‐CM (Comunidad de Madrid, Madrid, Spain) to T.I. and institutional grants to CBMSO from Fundación Ramón Areces and Fundación Banco de Santander to J.J.L. T.I. and J.J.L. are also funded by Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) and CIBERNED cooperative project 2015‐2/06 (Instituto de Salud Carlos III, Spain). GS work was supported by the Wellcome Trust Senior Investigator Award (107116/Z/15/Z), the European Union's Horizon 2020 Research and Innovation programme under grant agreement 739572 and a UK Dementia Research Institute Foundation award. A.S.‐S. was funded by a contract from CIBERNED‐2015‐2/06.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Altered levels and isoforms of Tau and nuclear membrane invaginations in Huntington's disease

  • Fernández-Nogales, Marta
  • Lucas, José Javier
Since the early reports of neurofibrillary Tau pathology in brains of some Huntington's disease (HD) patients, mounting evidence of multiple alterations of Tau in HD brain tissue has emerged in recent years. Such Tau alterations range from increased total levels, imbalance of isoforms generated by alternative splicing (increased 4R-/3R-Tau ratio) or by post-translational modifications such as hyperphosphorylation or truncation. Besides, the detection in HD brains of a new Tau histopathological hallmark known as Tau nuclear rods (TNRs) or Tau-positive nuclear indentations (TNIs) led to propose HD as a secondary Tauopathy. After their discovery in HD brains, TNIs have also been reported in hippocampal neurons of early Braak stage AD cases and in frontal and temporal cortical neurons of FTD-MAPT cases due to the intronic IVS10+16 mutation in the Tau gene (MAPT) which results in an increased 4R-/3R-Tau ratio similar to that observed in HD. TNIs are likely pathogenic for contributing to the disturbed nucleocytoplasmic transport observed in HD. A key question is whether correction of any of the mentioned Tau alterations might have positive therapeutic implications for HD. The beneficial effect of decreasing Tau expression in HD mouse models clearly implicates Tau in HD pathogenesis. Such beneficial effect might be exerted by diminishing the excess total levels of Tau or specifically by diminishing the excess 4R-Tau, as well as any of their downstream effects. In any case, since gene silencing drugs are under development to attenuate both Huntingtin (HTT) expression for HD and MAPT expression for FTD-MAPT, it is conceivable that the combined therapy in HD patients might be more effective than HTT silencing alone., CiberNed-ISCIII collaborative grants 2013/09-2, 2015-2/06 and 2018/06-5 to JL and by grants from Spanish Ministry of Science, Innovation, and Universities (MICINN): SAF2015-65371-R and RTI2018-096322-B-I00 to JL, by the European Union FEDER funds, the Fundación Botín by the Banco Santander through its Santander Universities Global Division and by Fundación Ramón Areces and Fundación Alicia Koplowitz
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington¿s disease

  • Picó, Sara
  • Parras, Alberto
  • Santos-Galindo, María
  • Pose-Utrilla, Julia
  • Castro, Margarita
  • Fraga, Enrique
  • Hernández Hernández, Ivo
  • Elorza, Ainara
  • Anta, Héctor
  • Wang, Nan
  • Martí-Sánchez, Laura
  • Belloc, Eulàlia
  • García-Esparcia, Paula
  • Garrido Jurado, Juan José
  • Ferrer, Isidro
  • Macías García, Daniel
  • Mir, Pablo
  • Artuch, Rafael
  • Pérez, Belén
  • Hernández, Félix
  • Navarro Medrano, Pilar
  • López-Sendón, José Luis
  • Iglesias, Teresa
  • Yang, Willian
  • Méndez, Raúl
  • Lucas, José Javier
Huntington’s disease (HD) is a hereditary neurodegenerative disorder of the basal ganglia for which disease-modifying treatments are not yet available. Although gene-silencing therapies are currently being tested, further molecular mechanisms must be explored to identify druggable targets for HD. Cytoplasmic polyadenylation element binding proteins 1 to 4 (CPEB1 to CPEB4) are RNA binding proteins that repress or activate translation of CPE-containing transcripts by shortening or elongating their poly(A) tail. Here, we found increased CPEB1 and decreased CPEB4 protein in the striatum of patients and mouse models with HD. This correlated with a reprogramming of polyadenylation in 17.3% of the transcriptome, markedly affecting neurodegeneration-associated genes including PSEN1, MAPT, SNCA, LRRK2, PINK1, DJ1, SOD1, TARDBP, FUS, and HTT and suggesting a new molecular mechanism in neurodegenerative disease etiology. We found decreased protein content of top deadenylated transcripts, including striatal atrophy–linked genes not previously related to HD, such as KTN1 and the easily druggable SLC19A3 (the ThTr2 thiamine transporter). Mutations in SLC19A3 cause biotin-thiamine–responsive basal ganglia disease (BTBGD), a striatal disorder that can be treated with a combination of biotin and thiamine. Similar to patients with BTBGD, patients with HD demonstrated decreased thiamine in the cerebrospinal fluid. Furthermore, patients and mice with HD showed decreased striatal concentrations of thiamine pyrophosphate (TPP), the metabolically active form of thiamine. High-dose biotin and thiamine treatment prevented TPP deficiency in HD mice and attenuated the radiological, neuropathological, and motor HD-like phenotypes, revealing an easily implementable therapy that might benefit patients with HD., This work was supported by CiberNed-ISCIII collaborative grants 2013/09-2 to J.J.L, 2015-2/06 and 2018/06-5 to J.J.L and T.I., and by grants SAF2015-65371-R (MINECO/AEI/FEDER, UE) and by grants from Spanish Ministry of Science, Innovation and Universities (MINECO/MICINN): RTI2018-096322-B-I00 (MCIU/AEI/FEDER, UE) to J.J.L., SAF2017- 88885-R (MINECO/AEI/FEDER, UE) to T.I., BFU2014-54122-P (MINECO/AEI/FEDER, UE) to R.M., and ISCIII-FEDER (PI17/00199) to P.N., by the European Union FEDER funds, the Fundación Botín by the Banco Santander through its Santander Universities Global Division, by Fundación BBVA and by Fundación Ramón Areces. A.P. and S.P. were recipients of FPI fellowships from MICINN/MINECO, A.P. was also recipient of a contract from CIBERNED, J.P.U. was contracted by SAF2017-88885-R (MINECO/AEI/FEDER, UE), D.M-G. was supported by the “Río Hortega” programme [CM18/00142] from ISCIII-FEDER, A.E. was recipient of Juan de la Cierva contracts from MICINN/MINECO.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pathogenic Mis-splicing of CPEB4 in Schizophrenia

  • Ollà, Ivana
  • Pardiñas, Antonio F.
  • Parras, Alberto
  • Hernández, Ivó H.
  • Santos-Galindo, María
  • Picó, Sara
  • Callado, Luis F.
  • Elorza, Ainara
  • Rodríguez-López, Claudia
  • Fernández-Miranda, Gonzalo
  • Belloc, Eulàlia
  • Walters, James T. R.
  • O'Donovan, Michael C.
  • Méndez, Raúl
  • Toma, Claudio
  • Meana, J. Javier
  • Owen, Michael J.
  • Lucas, José J.
Background: Schizophrenia (SCZ) is caused by an interplay of polygenic risk and environmental factors, which may alter regulators of gene expression leading to pathogenic misexpression of SCZ risk genes. The CPEB family of RNA-binding proteins (CPEB1–4) regulates translation of target RNAs (approximately 40% of overall genes). We previously identified CPEB4 as a key dysregulated translational regulator in autism spectrum disorder (ASD) because its neuronal-specific microexon (exon 4) is mis-spliced in ASD brains, causing underexpression of numerous ASD risk genes. The genetic factors and pathogenic mechanisms shared between SCZ and ASD led us to hypothesize CPEB4 mis-splicing in SCZ leading to underexpression of multiple SCZ-related genes. Methods: We performed MAGMA-enrichment analysis on Psychiatric Genomics Consortium genome-wide association study data and analyzed RNA sequencing data from the PsychENCODE Consortium. Reverse transcriptase polymerase chain reaction and Western blot were performed on postmortem brain tissue, and the presence/absence of antipsychotics was assessed through toxicological analysis. Finally, mice with mild overexpression of exon 4–lacking CPEB4 (CPEB4Δ4) were generated and analyzed biochemically and behaviorally. Results: First, we found enrichment of SCZ-associated genes for CPEB4-binder transcripts. We also found decreased usage of CPEB4 microexon in SCZ probands, which was correlated with decreased protein levels of CPEB4-target SCZ-associated genes only in antipsychotic-free individuals. Interestingly, differentially expressed genes fit those reported for SCZ, specifically in the SCZ probands with decreased CPEB4-microexon inclusion. Finally, we demonstrated that mice with mild overexpression of CPEB4Δ4 showed decreased protein levels of CPEB4-target SCZ genes and SCZ-linked behaviors. Conclusions: We identified aberrant CPEB4 splicing and downstream misexpression of SCZ risk genes as a novel etiological mechanism in SCZ., his work was supported by grants to JJL from: Networking Research Center on Neurodegenerative Diseases (CIBERNED) - Health Institute Carlos III (ISCIII) (Collaborative Grant No. PI2018/06-1), Spanish Ministry of Economy and Competitiveness (MINECO) (Grant No. SAF2015-65371-R), Spanish Ministry of Science, Innovation and Universities (MICIU) (Grant No. RTI2018-096322-B-I00) and Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033/FEDER,UE Grant No. PID2021-123141OB-I00); by grants to RM from MINECO (PID2020-119533GB-I00) and World Cancer Research Fund International (2020_021); by grants to CT: No. PID2020-114996RB-I00 (MCIU/AEI/FEDER,UE) and RyC2018-024106-I; and by grants to JJM and LFC from Basque Government (Grant Nos. IT-1211-19 and 1512-22). Cardiff University’s work was supported by grants to JTRW, MCO, and MJO from Medical Research Council Centre (Grant No. MR/L010305/1), Program (Grant No. MR/P005748/1), and Project (Grant Nos. MR/L011794/1, MC_PC_17212). AFP was supported by an Academy of Medical Sciences “Springboard” award (SBF005∖1083). IO was hired through European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement (Grant No. 766124). The Center for Molecular Biology Severo Ochoa is a Severo Ochoa Center of Excellence (MICIN, Award CEX2021-001154-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001154-S)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Huntington's disease-specific mis-splicing unveils key effector genes and altered splicing factors

  • Elorza, Ainara
  • Márquez, Yamile
  • Cabrera, Jorge
  • Sánchez-Trincado, José Luis
  • Santos-Galindo, María
  • Hernández, Ivó H.
  • Picó, Sara
  • Díaz-Hernández, Juan I.
  • García-Escudero, Ramón
  • Irimia Martínez, Manuel
  • Lucas, José J.
Correction of mis-splicing events is a growing therapeutic approach for neurological diseases such as spinal muscular atrophy or neuronal ceroid lipofuscinosis 7, which are caused by splicing-affecting mutations. Non-mutation harboring mis-spliced effector genes are also good candidate therapeutic targets in diseases with more complex etiologies such as cancer, autism, muscular dystrophies or neurodegenerative diseases. Next-generation RNA sequencing (RNA-seq) has boosted investigation of global mis-splicing in diseased tissue to identify such key pathogenic mis-spliced genes. Nevertheless, while analysis of tumour or dystrophic muscle biopsies can be informative on early stage pathogenic mis-splicing, for neurodegenerative diseases, these analyses are intrinsically hampered by neuronal loss and neuroinflammation in post-mortem brains. To infer splicing alterations relevant to Huntington's disease (HD) pathogenesis, here we performed intersect-RNA-seq analyses of human post-mortem striatal tissue and of an early symptomatic mouse model in which neuronal loss and gliosis are not yet present. Together with a human/mouse parallel motif scan analysis, this approach allowed us to identify the shared mis-splicing signature triggered by the HD-causing mutation in both species and to infer upstream deregulated splicing factors. Moreover, we identified a plethora of downstream neurodegeneration-linked mis-spliced effector genes that -together with the deregulated splicing factors- become new possible therapeutic targets. In summary, here we report pathogenic global mis-splicing in HD striatum captured by our new intersect-RNA-seq approach that can be readily applied to other neurodegenerative diseases for which bona fide animal models are available., grants PI2015-2/06-3 and PI2018/06-1 ; by grants : SAF2015-65371-R (MINECO/AEI/FEDER, UE) ; RTI2018-096322-B-I00 (MCIU/AEI/FEDER, UE) from Spanish Ministry of Economy and Competitiveness/Ministry of Science, Innovation and Universities (MINECO/MICINN) to JJL and BFU2017-89201-P (MINECO/AEI/FEDER, UE) to MI; PI18/00263 from the Instituto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness) co-funded by the European Regional Development Fund- to RG-E; institutional grant from Fundación Ramón Areces to CBMSO ; Fundación BBVA to JJL; and by the European Research Council under the European Union's Horizon 2020 research and innovation program ERC-StG-LS2-637591 to MI
Docta Complutense
Publication Artículo científico (JournalArticle)

The regulation of proteostasis in glial cells by nucleotide receptors is key in acute neuroinflammation

  • De Diego García, Laura
  • Sebastián Serrano, Álvaro
  • Hernández, I.H.
  • Pintor Just, Jesús Jerónimo
  • Lucas, Jose Javier
  • Díaz Hernández, Miguel
The disturbances of cellular proteostasis caused by the alteration in the ubiquitin-proteasome system (UPS) have been proposed as a common mechanism underlying several neural pathologies that involve a neuro-inflammatory process. As we have previously reported that the nucleotide receptor P2Y purinoceptor 2 (P2Y2R) regulates the proteasomal catalytic activities, we wonder whether this receptor is involved in the UPS disturbances associated with the neuroinflammation process. With the use of mice expressing a UPS reporter [mice expressing the UPS reporter ubiquitinG76V -green fluorescent protein (UbGFP mice)], we found that LPS-induced acute neuroinflammation status causes a UPS impairment in astrocytes and microglial cells by a mechanism dependent on P2Y2R. In this line, LPS-treated double transgenic UbGFP; P2Y2R−/− mice did not present a UPS impairment in astrocytes or a social interaction deficit as severe as that observed in LPS-treated UbGFP mice. In vivo administration of selective P2Y2R agonist diuridine tetraphosphate reversed the UPS impairment completely in astrocytes and partially in microglial cells, promoting increased expression of the proteasomal β5 subunit by a mechanism dependent on the Src/ PI3K/ERK pathway. Altogether, our results suggest that LPS induces unbalanced proteostasis in astrocytes by blocking P2Y2R. Finally, our findings point to the design of selective P2Y2R agonist drugs as a new therapeutic approach to treat the neuroinflammatory status.